Servier Expands Base4 Partnership to Advance Neuroscience Drug Development
Discover our news
Nicolas Garnier joins Servier as Chief Patient Officer
Data at ASH 2023 Underscores Servier Leadership in Hard-to-Treat Hematologic Malignancies
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
New Vorasidenib Data at SNO 2023 Bolster Servier’s Neuro-Oncology Clinical Development Program
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Servier To Showcase Clinical Advances Across its Oncology Pipeline at ESMO 2023
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress